Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS) : A report from the European MDS registry
© 2022 British Society for Haematology and John Wiley & Sons Ltd..
Information on causes of death (CoDs) and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower-risk MDS (LR-MDS) is limited. A better understanding of the relationship between disease characteristics, clinical interventions and CoDs may improve outcomes of patients with LR-MDS. We prospectively collected data on patients with LR-MDS in the European MDS registry from 2008 to 2019. Clinical, laboratory and CoDs data were obtained. To examine MDS-specific survival, relative survival (RS) was estimated using national life tables. Of 2396 evaluated subjects, 900 died (median overall survival [OS]: 4.7 years; median follow-up: 3.5 years). The most common CoDs were acute myeloid leukaemia/MDS (20.1%), infection (17.8%) and cardiovascular disease (CVD; 9.8%). Patients with isolated del(5q) and with red cell transfusion needed during the disease course, had a higher risk of fatal CVD. The 5-year OS was 47.3% and the 5-year RS was 59.6%, indicating that most patients died due to their underlying MDS. Older patients (aged >80 years) and the lowest-risk patients were more likely to die from competing causes. This study shows that MDS and its related complications play crucial role in the outcome of patients with LR-MDS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:200 |
|---|---|
| Enthalten in: |
British journal of haematology - 200(2023), 4 vom: 07. Feb., Seite 451-461 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mądry, Krzysztof [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Causes of death |
|---|
| Anmerkungen: |
Date Completed 06.02.2023 Date Revised 14.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.18542 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348498519 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348498519 | ||
| 003 | DE-627 | ||
| 005 | 20231226040400.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.18542 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348498519 | ||
| 035 | |a (NLM)36335984 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mądry, Krzysztof |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS) |b A report from the European MDS registry |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.02.2023 | ||
| 500 | |a Date Revised 14.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a Information on causes of death (CoDs) and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower-risk MDS (LR-MDS) is limited. A better understanding of the relationship between disease characteristics, clinical interventions and CoDs may improve outcomes of patients with LR-MDS. We prospectively collected data on patients with LR-MDS in the European MDS registry from 2008 to 2019. Clinical, laboratory and CoDs data were obtained. To examine MDS-specific survival, relative survival (RS) was estimated using national life tables. Of 2396 evaluated subjects, 900 died (median overall survival [OS]: 4.7 years; median follow-up: 3.5 years). The most common CoDs were acute myeloid leukaemia/MDS (20.1%), infection (17.8%) and cardiovascular disease (CVD; 9.8%). Patients with isolated del(5q) and with red cell transfusion needed during the disease course, had a higher risk of fatal CVD. The 5-year OS was 47.3% and the 5-year RS was 59.6%, indicating that most patients died due to their underlying MDS. Older patients (aged >80 years) and the lowest-risk patients were more likely to die from competing causes. This study shows that MDS and its related complications play crucial role in the outcome of patients with LR-MDS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a causes of death | |
| 650 | 4 | |a myelodysplastic syndromes | |
| 650 | 4 | |a relative survival | |
| 700 | 1 | |a Lis, Karol |e verfasserin |4 aut | |
| 700 | 1 | |a Fenaux, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Bowen, David |e verfasserin |4 aut | |
| 700 | 1 | |a Symeonidis, Argiris |e verfasserin |4 aut | |
| 700 | 1 | |a Mittelman, Moshe |e verfasserin |4 aut | |
| 700 | 1 | |a Stauder, Reinhard |e verfasserin |4 aut | |
| 700 | 1 | |a Čermák, Jaroslav |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz, Guillermo |e verfasserin |4 aut | |
| 700 | 1 | |a Hellström-Lindberg, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Langemeijer, Saskia |e verfasserin |4 aut | |
| 700 | 1 | |a Malcovati, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Germing, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Holm, Mette Skov |e verfasserin |4 aut | |
| 700 | 1 | |a Guerci-Bresler, Agnes |e verfasserin |4 aut | |
| 700 | 1 | |a Culligan, Dominic |e verfasserin |4 aut | |
| 700 | 1 | |a Sanhes, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Kotsianidis, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a van Marrewijk, Corine |e verfasserin |4 aut | |
| 700 | 1 | |a Crouch, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a de Witte, Theo |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Alex |e verfasserin |4 aut | |
| 700 | 0 | |a EUMDS Registry Participants |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 200(2023), 4 vom: 07. Feb., Seite 451-461 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:200 |g year:2023 |g number:4 |g day:07 |g month:02 |g pages:451-461 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.18542 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 200 |j 2023 |e 4 |b 07 |c 02 |h 451-461 | ||